Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (182)
  2. Journal Article (79)
  3. Research Letter (18)
  4. Review (18)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (310)
  2. Hematologic Malignancies, Division of (310)
  3. Center for Hematologic Malignancies (168)
  4. Lymphoma (164)
  5. Hematology-Oncology Fellows (141)
  6. Survivorship Research (118)

More Groups

People
  1. Maria Palomba (112)
  2. Andrew Zelenetz (76)
  3. Anita Kumar (66)
  4. Lorenzo Falchi (66)
  5. Gunjan Shah (63)
  6. Miguel-Angel Perales (60)

More People

Years
  1. 2025 (26)
  2. 2024 (68)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (127)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (18)
  4. Blood Advances (16)
  5. Haematologica (15)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (21)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (15)
  6. Nature Publishing Group (14)

More Publishers

Results (310)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study
    Meeting Abstract

    Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Lenz, G.; Trneny, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; Sharman, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (soc) therapy in ZUMA-7
    Meeting Abstract

    Locke, F. L.; Oluwole, O. O.; Kuruvilla, J.; Thieblemont, C.; Morschhauser, F.; Salles, G.; Rowe, S. P.; Vardhanabhuti, S.; Filosto, S.; To, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study
    Meeting Abstract

    Qualls, D.; Buege, M. J.; Dao, P.; Caimi, P. F.; Rutherford, S. C.; Wehmeyer, G.; Romancik, J. T.; Leslie, L. A.; Merrill, M. H.; Crombie, J. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
    Journal Article

    Salles, G.; Schuster, S. J.; Dreyling, M.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; von Tresckow, B.; Smith, S. M.; Jiménez-Ubieto, A.; Davis, K. L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
    Journal Article

    Berndt, S. I.; Vijai, J.; Benavente, Y.; Camp, N. J.; Nieters, A.; Wang, Z.; Smedby, K. E.; Kleinstern, G.; Hjalgrim, H.; Besson, C.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin + rituximab, cyclophosphamid, doxorubicin und prednison (Pola-R-CHP) im vergleich zu rituximab, cyclophosphamid, doxorubicin, vincristin und prednison (R-CHOP) bei patient: Innen mit unbehandeltem diffusemgroßzelligem B-zell-lymphom (DLBCL): Ergebnisse der phase III POLARIX studie
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study
    Meeting Abstract

    Trneny, M.; Fogliatto, L.; Gardner, F. P.; Flinn, I. W.; Larouche, J. F.; Haioun, C.; Albendea, M. A. C.; Goto, H.; Hajek, R.; Salles, G. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P. A.; Kim, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save